Questions 1 – 2: Specify the indication for CIBMTR data reporting
Indicate whether the individual will be receiving an Infusion (e.g., hematopoietic cellular transplant (HCT), gene therapy, cellular therapy), Marrow toxic injury, or Non-cellular therapy (e.g., chemotherapy, immunotherapy, etc.).
For more information on infusion types, review Appendix D.
Marrow toxic injury should only be reported by Radiation Injury Treatment Network (RITN) centers in the event of mass casualty incident resulting in marrow toxic injury. Do not report marrow toxic injury for individuals receiving pre-infusion radiation therapy or for accidental, isolated exposures to radiation. If the indication is Marrow toxic injury, specify the date of the marrow toxic injury (i.e., radiation event).
If completing this form for a patient at a RITN center and it is uncertain if the patient’s data should be reported using the marrow toxic injury indication, contact CIBMTR Center Support or email RITN@nmdp.org.
Non-cellular therapy may include vaccine or immunomodulatory trials; report non-cellular therapy when the patient is enrolled on a trial or protocol requiring data submission to CIBMTR.
Section Updates:
| Question Number | Date of Change | Add/Remove/Modify | Description | Reasoning (If applicable) |
|---|---|---|---|---|
| . | . | . | . | . |
Need more help with this?
Don’t hesitate to contact us here.